Birth-genome screening could reshape early childhood care
TL;DR
Global genomic newborn-screening studies (eg, GUARDIAN, BabyScreen+, BabyDetect) are testing broad sequencing on dried-blood spots to flag treatable conditions not covered by traditional panels. Early results suggest confirmable findings in about 1–3% of infants, with some cases prompting life-saving interventions like bone-marrow transplants and earlier seizure treatment. While promising, researchers and ethicists debate cost, scalability, which genes/conditions to include, how to report results, and the potential for privacy or discrimination, as families’ experiences with counseling and communication vary.
Topics:healthpublic-health#genetic-disorders#genomics#newborn-screening#note-extra-tag-not-allowed-in-top5#precision-medicine#public-health
- Screening babies’ genomes could save lives. Here’s how it would work nature.com
- Population-based genomic detection of childhood cancer predisposition using newborn dried blood spots nature.com
- Newborn screening for cancer risk could save lives. Should it be done? Science News
- Simone Cesaro: Potential of Neonatal Screening for Pediatric Cancer Predisposition Oncodaily
- Genomic Newborn Screening Could Identify Some Children at Risk for Early Cancers Technology Networks
Want the full story? Read the original reporting
Read on nature.com